US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Here are some of the recent management changes that took place during the week: Biogen (NASDAQ:BIIB) said its Executive Vice ...

Fintel reports that on October 31, 2024, Morgan Stanley downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

We recently compiled a list of the 10 Best QQQ Stocks to Buy According to Analysts. In this article, we are going to take a ...

We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $275.00. Phil ...

Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority ...

Market watchers, throughout the week, observed several Wall Street executives stepping up for new roles as part of leadership reshuffling. Meanwhile, some companies such as Biogen, U.S. Bancorp ...